Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression

Open access

Abstract

Background: Major depressive disorder (MDD) is a highly burdensome health condition, for which there are numerous accepted pharmacological and psychological interventions. Adjunctive treatment (augmentation/combination) is recommended for the ~50% of MDD patients who do not adequately respond to first-line treatment. We aimed to evaluate the current evidence for concomitant approaches for people with early-stage treatment-resistant depression (TRD; defined below). Methods: We systematically searched Medline and Institute for Scientific Information Web of Science to identify randomised controlled trials of adjunctive treatment of ⩾10 adults with MDD who had not responded to ⩾1 adequate antidepressant. The cochrane risk of bias (RoB) tool was used to assess study quality. Pre-post treatment meta-analyses were performed, allowing for comparison across heterogeneous study designs independent of comparator interventions. Results: In total, 115 trials investigating 48 treatments were synthesised. The mean intervention duration was 9 weeks (range 5 days to 18 months) with most studies assessed to have low ( n = 57) or moderate ( n = 51) RoB. The highest effect sizes (ESs) were from cognitive behavioural therapy (ES = 1.58, 95% confidence interval (CI): 1.09–2.07), (es)ketamine (ES = 1.48, 95% CI: 1.23–1.73) and risperidone (ES = 1.42, 95% CI: 1.29–1.61). Only aripiprazole and lithium were examined in ⩾10 studies. Pill placebo (ES = 0.89, 95% CI: 0.81–0.98) had a not inconsiderable ES, and only six treatments’ 95% CIs did not overlap with pill placebo’s (aripiprazole, (es)ketamine, mirtazapine, olanzapine, quetiapine and risperidone). We report marked heterogeneity between studies for almost all analyses. Conclusions: Our findings support cautious optimism for several augmentation strategies; although considering the high prevalence of TRD, evidence remains inadequate for each treatment option.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/02698811221104058

Cites

Statistics

Figures

Figure 1. PRISMA flow diagram. TRD: treatment-resistant depression.
Figure 1. PRISMA flow diagram. TRD: treatment-resistant depression.CC BY · PubMed Central
Figure 2. Forest plot displaying ESs for treatments examined in >3 studies.
Figure 2. Forest plot displaying ESs for treatments examined in >3 studies.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 43 · Cited by 87

Research works printed but not linked: 6

  1. Fava M, 2007, Psychiatry (Edgmont), 4, 16
  2. Higgins JPT, 2022, Cochrane Handbook for Systematic Reviews of Interventions
  3. Lakens D, 2013, Front Psychol, 26, 863
  4. Suehs BT, 2008, Texas Medication Algorithm Project Procedural Manual: Major Depressive Disorder Algorithms
  5. Thase ME, 1997, J Clin Psychiatry, 58, 23
  6. World Health Organisation, 2017, Depression and Other Common Mental Disorders: Global Health Estimates

Metadata

Authors
Scott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., Young, A. H., & Strawbridge, R.
Affiliations
  • South London and Maudsley NHS Foundation Trust (GB)
  • King's College London (GB)
  • Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
Corresponding author
Strawbridge, Rebecca
Venue
Journal of Psychopharmacology
Published
2022-07-21
Volume
37
Issue
3
Pages
268-278
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W4286500354
Cited by
87
References
43
Citations by year
2026: 23 · 2025: 19 · 2024: 26 · 2023: 15 · 2022: 4
FWCI
2.29
Type
journal article
Language
en
Open access
Locations
  • Journal of Psychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion, other-oa)
Funders
NIHR Maudsley Biomedical Research Centre (n/a)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords
treatment-resistant depression, major depressive disorder, adjunctive therapy, antidepressant augmentation, cognitive behavioral therapy, esketamine, risperidone, aripiprazole, lithium, mirtazapine, olanzapine, quetiapine, placebo response
MeSH terms
Aripiprazole, Adult, Depression, Major Depressive Disorder, Humans, Ketamine, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. https://app.cochat.ai/papers/10.1177/02698811221104058
The paper
Scott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., Young, A. H., & Strawbridge, R. (2023). Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. Journal of Psychopharmacology. https://doi.org/10.1177/02698811221104058

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.